Abstract:Impressive outcomes in therapeutic radiation oncology have been achieved in the past decade through the development of advanced computer technology and imaging methods, such as intensity modulated radiotherapy. Ideally, radiotherapy treatment delivers a high dose to the tumor while sparing the surrounding healthy tissues and organs at risk from radiation damage. Spatiotemporal Fractionated Radiotherapy has emerged as an innovative technique that delivers different dose distributions to different parts of the tumor in order to achieve high doses to the target while ensuring a low dose-bath in the surrounding normal tissue. Spatiotemporally fractionated regimens showed in silico up to 10 - 15% sparing of normal tissue from radiation damage, while ensuring isoeffective tumor control compared to conventionally fractionated regimens. However, prior to advancing spatiotemporal fractionation to the clinical level, it is important to probe the validity of the main assumption of spatiotemporal fractionation derived from the Biologically Effective Dose (BED) model: two different fractionation schemes that implement a high and a low dose will lead to equivalent clinical effects, regardless of dose-treatment sequence. A tumor growth delay study was performed in a subcutaneous immunocompetent murine tumor model (MC38-tumor cell derived) receiving two different fractionation regimens. Particularly, tumors belonging to the two treatment groups received the same dose combination - a high (12 Gy) and a low (6 Gy) dose fraction separated by 72 hours - with the doses delivered in opposite order in the two treatment groups. The same experimental outline was performed in a subcutaneous immunodeficient murine tumor model derived from the same tumor cells. Tumors were also characterized by immunophenotyping analysis seven days after first irradiation. Even though the two regimens deliver the same physical dose to the tumor - and would be considered equivalent according to the BED model - different tumor growth delays were observed in a time window of 30 days after first irradiation depending on the treatment group. Such differences were observed in the immunocompetent model but not in the immunodeficient model. The immunophenotyping results showed immunostimulatory vs immunosuppressive phenotypes of the tumor microenvironment depending on the order of the treatment doses. An additional tumor growth delay study including immune checkpoint inhibitors confirmed the fundamental role of the immune system with the differential efficacy outcomes of the two regimens. Overall, these intriguing results suggest that a differential radiotherapy-induced immune response to different doses of ionizing radiation plays an important role in the treatment outcome and asks for re-evaluation of the BED model taking scheduling-dependent parameters into consideration. Citation Format: Irene Vetrugno, Irma Telarovic, Nathan Torelli, Jan Unkelbach, Martin Pruschy. Spatiotemporal fractionation: An innovative concept of fractionated radiotherapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 2879.

Immune System -- Tumor Efficiency Rate as a new Oncological Index for Radiotherapy Treatment Optimization

The Optimal Radiation Dose to Induce Robust Systemic Anti-Tumor Immunity

Dynamical behavior-based approach for the evaluation of treatment efficacy: The case of immuno-oncology

A biomathematical model of tumor response to radioimmunotherapy with $α$PDL1 and $α$CTLA4

Mathematical Modeling of the Synergetic Effect between Radiotherapy and Immunotherapy

In silico tumor control induced via alternating immunostimulating and immunosuppressive phases

Modeling and analysis of nonlinear tumor‐immune interaction under chemotherapy and radiotherapy

The Top Quark - 2006 and Beyond

A general framework for modeling tumor-immune system competition and immunotherapy: mathematical analysis and biomedical inferences

Dynamics aspects and bifurcations of a tumor-immune system interaction under stationary immunotherapy

Behavior of tumors under nonstationary theraphy

From tumor microenvironment to immuno-therapeutic outcomes for solid tumors: A systems theoretic approach

A Mathematical Tumor Model with Immune Resistance and Drug Therapy: An Optimal Control Approach

Modeling the dynamics of mixed immunotherapy and chemotherapy for the treatment of immunogenic tumor

Parameter estimation and treatment optimization in a stochastic model for immunotherapy of cancer

Computational Approach for Spatially Fractionated Radiation Therapy (SFRT) and Immunological Response in Precision Radiation Therapy

Oscillations of the number of immune system cells in a space-velocity thermostatted kinetic theory model of tumor growth

Mathematical modeling and dynamic analysis of anti-tumor immune response

A Theoretical Model for Predicting and Optimizing in Vitro Screening of Potential Targeted Alpha-Particle Therapy Drugs

Improving cancer treatments via dynamical biophysical models

Abstract 2879: Spatiotemporal fractionation: An innovative concept of fractionated radiotherapy